3rd Quarter - Report

NOVARTIS for NOVARTIS

Firm
Client
Income
—
Expenses
$1,430,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Provide Medicare Part B Coverage for Vaccines Covered under Part D Medicaid Coverage of Vaccines Biosimilars

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS New —
WENDY P SUSSMAN New —
JASON BENJAMIN VAN PELT —

Contacted: State, Dept of (DOS); SENATE; HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); U.S. Trade Representative (USTR); White House Office; Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA)

Budget/Appropriations BUD

Pandemic Influenza Funding FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2015 Labor HHS Appropriations Bill

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
WENDY P SUSSMAN New —
JASON BENJAMIN VAN PELT —

Contacted: White House Office; SENATE; U.S. Trade Representative (USTR); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Health Issues HCR

S.2041 - Promoting Life-Saving New Therapies for Neonates Act of 2015 S.481 - Improving Regulatory Transparency for New Medical Therapies Act H.R.2841 - Fair Access for Safe and Timely Generics Act of 2015 Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act FSA/HSA - Support reinstating coverage of OTC products HR351/S351 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Medical Device Tax Repeal Drug Importation Reimbursement for medical devices GMP related to manufacturing sites Federal BTC and GMO labeling laws Biosimilars 21st Century Cures PDUFA 340B Drug Discount Program Low-income Subsidy in Part D REMS FCLCA

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SARAH HALLER —
SHAWN O'NEAIL —
CANDICE PHIPPS New —
WENDY P SUSSMAN New —
JASON BENJAMIN VAN PELT —

Contacted: State, Dept of (DOS); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Commerce, Dept of (DOC); SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: S. 481 (114th), S. 2041 (114th), H.R. 2841 (114th), H.R. 351 (114th)

Trade (domestic/foreign) TRD

Free Trade Agreements: - Intellectual Property and Transparency Provisions - Free Trade Agreements Access to Medicines Issues Global Health Issues India and Canada IP and market Access Issues Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines Global Intellectual Property Issues Including: - Trade Promotion Authority - Trans-pacific Partnership - Trans Atlantic Trade and Investment Partnership HR3830/S1900 - Bipartisan Congressional Trade Priorities Act of 2014 International Market Access and Intellectual Property Issues Biopharmaceutical Innovation Policies

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
LEO A FARBER —
SARAH HALLER —
JASON BENJAMIN VAN PELT —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; State, Dept of (DOS); Commerce, Dept of (DOC)

Bills named: H.R. 3830 (114th)

Taxation/Internal Revenue Code TAX

ACA Pharmaceutical Industry Fee Exclusions R&D Tax Credit Anti-Inversion Tax H.R.3618 - Orphan Drug Fairness Act S.1906 - Orphan Drug Fairness Act

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS New —
JASON BENJAMIN VAN PELT —

Contacted: HOUSE OF REPRESENTATIVES; Commerce, Dept of (DOC); White House Office; Food & Drug Administration (FDA); SENATE; State, Dept of (DOS); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); U.S. Trade Representative (USTR)

Bills named: H.R. 3618 (114th), S. 1906 (114th)

Copyright/Patent/Trademark CPT

HR3116 MODDERN Cures Act of 2013 Data Exclusivity Trade Secrets Intellectual Property Biopharmaceutical Innovation Policy Issues Biologics Data Protection Issues Draft Legislation on Trade Secret Issues

Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

LobbyistCovered position, as disclosed
DANIEL CASSERLY —
LEO A FARBER —
SHAWN O'NEAIL —
CANDICE PHIPPS New —
JASON BENJAMIN VAN PELT —

Contacted: SENATE; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); State, Dept of (DOS); U.S. Agency for International Development (USAID)

Bills named: H.R. 3116 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.